Gene Editing Services for Cancer Research
Inquiry
As a preclinical CRO specializing in oncology, Alfa Cytology provides comprehensive gene editing services designed to accelerate your cancer research and drug discovery programs. Built upon a CRISPR/Cas9 core platform and integrated with complementary technologies including base editing, prime editing, and CRISPRi/a, our experienced scientists deliver high-quality, reproducible gene editing solutions tailored to your specific research needs. Leveraging advanced technology platforms and deep oncology expertise, we support every stage of your drug discovery pipeline, from target identification and validation through IND-enabling studies.
Introduction to Gene Editing
Gene editing has revolutionized cancer research by enabling precise, targeted genome modifications, establishing direct causal links between genotype and phenotype. The CRISPR/Cas9 system has emerged as the most transformative tool in oncology, allowing researchers to elucidate gene function, model disease mechanisms, and validate therapeutic targets with unprecedented efficiency. Beyond CRISPR/Cas9, next-generation technologies, including base editing, prime editing, CRISPRi/a, and RNA-targeting systems, have further expanded the toolkit, enabling applications from single-nucleotide correction to transcriptional modulation without permanent genomic alteration. In cancer research, gene editing facilitates the generation of isogenic cell lines, disease-relevant animal models, and genome-wide functional screens, accelerating drug discovery from target identification through preclinical validation. As these technologies mature, their integration with multi-omics profiling, spatial analysis, and in vivo modeling is expected to further accelerate the translation of genetic insights into actionable therapeutic strategies, positioning gene editing as an indispensable component of modern oncology drug discovery.
Fig. 1 Use of CRISPR-Cas9 technology for the editing of tumor driver genes and its effect on the biological behavior of tumor cells. (Liu B, et al.; 2024)
Our Services
Our gene editing services cover the full spectrum of your research needs, from assessing editing precision and constructing custom libraries, to generating stable knockout, knockin, and point mutation models in both cell lines and mice. Each service is supported by rigorous quality control and comprehensive validation to ensure reproducible, publication-ready results.
Provides unbiased genome-wide detection of Cas9-induced double-strand breaks, identifying both on-target and off-target cleavage sites. This service delivers critical data for optimizing guide RNA design and ensuring safety profiles for regulatory submissions.
We design and construct custom CRISPR libraries for genome-wide knockout screens, pathway-focused investigations, or targeted validation. Our platform supports CRISPR knockout, CRISPRi, and CRISPRa applications, with scalable production from small-scale to genome-wide libraries.
Our CRISPR/Cas9-based gene knockout services deliver complete, stable gene disruption across a wide range of cell types. We employ optimized delivery systems and rigorous clonal selection with comprehensive validation at genomic and protein levels. This service is also applicable to mouse model generation.
Our knockin services leverage proprietary HDR enhancement technologies for precise integration of exogenous sequences. Applications include introduction of oncogenic mutations, fluorescent/luciferase tagging, and cell-based reporter system development. We also support knockin in mouse models.
We introduce targeted nucleotide changes using CRISPR-mediated editing and our proprietary prime editing platform. This platform supports point mutation generation in both cell lines and mouse models, delivering accurate mutation models for functional genomics and disease research.
Our RNP services deliver pre-assembled Cas9–sgRNA complexes directly into cells, achieving rapid editing with reduced off-target effects. This approach is particularly suitable for primary cells and sensitive cell lines.
Leveraging CRISPR/Cas9 technology, we have established an efficient and reliable gene editing platform that provides core tools for cancer gene function research and drug target validation. The platform integrates advanced guide RNA design algorithms, flexible delivery systems (plasmid/lentivirus/AAV/RNP), and end-to-end quality control frameworks, supporting a broad range of editing applications including gene knockout, knock-in, point mutation, and transcriptional regulation.
- High Editing Efficiency
- Low Off-Target Risk
- Broad System Compatibility
- Comprehensive Validation
Available Gene Editing Technologies
Alfa Cytology offers a comprehensive suite of gene editing technologies, enabling precise genome modification across the full spectrum of cancer research applications. The table below provides a comparison of available technologies to guide your selection based on specific research needs.
| Technology |
Editing Type |
Key Features |
Best For |
Limitations |
| Base Editing |
Single-nucleotide conversions (C→T, A→G) |
No DSBs required; precise nucleotide conversion without donor template |
Patient-specific point mutation modeling |
Single-base changes only; no knockout capability |
| Prime Editing |
All 12 base-to-base conversions; small insertions/deletions |
No DSBs required; versatile "search-and-replace" functionality; no donor template needed |
Complex mutation modeling, small fragment editing |
Lower efficiency in some cell types |
| CRISPRi / CRISPRa |
Gene expression modulation (downregulation/upregulation) |
Reversible gene regulation without permanent genome alteration |
Essential gene studies, pathway analysis |
Transient effects; no permanent models |
| RNAi |
Gene silencing |
Established technology; widely validated for loss-of-function studies |
Gene knockdown validation |
Off-target effects; incomplete silencing |
| Cas13 |
RNA knockdown |
Programmable RNA targeting with high specificity |
Transcript-level regulation |
RNA-level only |
| CRISPR/Cas9 |
Gene knockout, knockin, point mutation, genome-wide screening |
Simple design, cost-effective, high-throughput compatible; multiple Cas9 variants (SpCas9, SaCas9, high-fidelity) |
Gene knockout, genome-wide screening, cell line engineering |
Requires DSBs; off-target risks |
Gene Editing Applications in Cancer Research
Gene editing technologies provide powerful tools across all stages of cancer research, from basic mechanistic exploration to preclinical drug development. The table below organizes applications by research stage to help you quickly identify relevant solutions.
Target Discovery
- Genome-wide CRISPR screens
- Synthetic lethality screening
- Non-coding region functional analysis
Target Validation
- Functional validation of driver genes
- Isogenic cell line generation
- Point mutation model generation
Preclinical Evaluation
- Resistance model generation
- Target dependency validation
- IND-enabling data packages
Service Highlights
- Comprehensive Technology Portfolio: From CRISPR/Cas9 knockout to base editing, prime editing, and CRISPRi/a, we offer the full spectrum of gene editing technologies to meet diverse research objectives.
- End-to-End Support: We support every stage of your drug discovery pipeline, from target identification and validation through IND-enabling studies, under one integrated platform.
- High Editing Efficiency: Our optimized delivery systems (plasmid/lentivirus/AAV/RNP) and proprietary HDR enhancement technologies ensure robust editing across a wide range of cell types and model systems.
- Cell Line & Mouse Model Capabilities: We support gene editing in both cell lines and mouse models, enabling seamless translation from in vitro validation to in vivo efficacy studies.
Alfa Cytology integrates cutting-edge gene editing technologies with rigorous project management and scientific excellence. Whether you are exploring novel gene functions, building disease models, or advancing therapeutic candidates toward the clinic, we are your trusted partner in accelerating cancer research. Ready to accelerate your cancer research with our gene editing services? Please don't hesitate to contact us to discuss your project and discover how Alfa Cytology can support your drug discovery journey, from target discovery through IND-enabling studies.
Reference
- Liu B, et al. Research into overcoming drug resistance in lung cancer treatment using CRISPR-Cas9 technology: a narrative review. Transl Lung Cancer Res. 2024;13(8):2067-2081.
For research use only.
Related Services
